April 2010
Volume 51, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2010
12 Months Follow-Up of Combined Therapy With Intravitreal Injections of Ranibizumab +/- Triamcinolone Associated With Photodynamic Therapy Reduced Fluence (pdt) in Patients With Exsudative Age-Related Macular Degeneration (wamd)
Author Affiliations & Notes
  • A. Deudon Combe
    liberal, Strasbourg, France
  • Footnotes
    Commercial Relationships  A. Deudon Combe, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science April 2010, Vol.51, 99. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      A. Deudon Combe; 12 Months Follow-Up of Combined Therapy With Intravitreal Injections of Ranibizumab +/- Triamcinolone Associated With Photodynamic Therapy Reduced Fluence (pdt) in Patients With Exsudative Age-Related Macular Degeneration (wamd). Invest. Ophthalmol. Vis. Sci. 2010;51(13):99.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To assess the mean 12 months efficacy (VA assessment) in patients receiving combined therapy with intravitreal injections (IVT) of ranibizumab +/- triamcinolone associated with photodynamic therapy reduced fluence (PDT).

Methods: : Non-comparative retrospective analysis on 60 patients with exsudative age-related macular degeneration (wAMD) treated at baseline with a tritherapy associating PDT reduced-fluence (300mW/cm²) and the week after Intravitreal injections (IVT) of Ranibizumab 0.5mg + triamcinolone 4mg. Patients were retreated as needed with a combined therapy : PDT + Ranibizumab +/- triamcinolone according to retreatment criteria mainly based on OCT and FA examinations.

Results: : On the 60 patients 35 (58.3%) has received tritherapy cycles after the initial treatment. the mean number of treatments was 2.48 during the 12 months follow-up. The mean VA at baseline was 28.35 letters and the mean VA change versus baseline was +2.1 letters. six patients (10%) gained more than 15 letters, 33 patients (55%) gained more than 0 letters and 2 patients (3.3%) lost more than 15 letters. The treatment was generaly well tolerated with no serious adverse events. Only one patient presented a pseudo-uveitis associated with intraocular pressure increase after tritherapy.

Conclusions: : this approach combining 3 treatments such as PDT -reduced fluence + Ranibizumab + /- triamcinolone showed a trend to vision stabilization with less treatments cycles despite the low baseline VA of patients included in this retrospective analysis. This approach should be further evaluated in prospective clinical trials.

Keywords: clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials • retinal neovascularization • retina 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×